肿瘤恶液质药物治疗进展

Research progress of drug therapy for cancer cachexia

肿瘤恶液质主要表现为肌肉质量的逐渐减少与厌食、疲劳、功能状态受损,其中以胃肠道及肺恶性肿瘤最常见,严重影响患者的生活质量及生存时间。药物治疗在综合治疗中占据重要地位,但目前临床较为常用的药物,如食欲刺激剂和一些控制症状的药物,疗效不尽如人意。近年来,许多代谢调节剂、靶向药物及中医中药在肿瘤恶液质的治疗中展现出良好的疗效及耐受性,如促进生长和合成代谢的激素食欲刺激素类似物和抑制分解代谢的单克隆抗体等。治疗恶液质需要临床多学科协作进行全方位的干预,才有可能控制甚至逆转。本文就现今药物治疗方面的进展展开阐述。

Cancer cachexia mainly contains the gradual decrease of muscle mass,anorexia,fatigue,and impaired functional status,which seriously affects the quality of life and survival time of patients.Among them,gastrointestinal and pulmonary malignancies are the most common.Drug therapy plays an important role in the comprehensive treatment,but currently the more commonly used drugs,such as appetite stimulants and some drugs to control symptoms,have unsatisfactory efficacy.In recent years,many metabolic regulators,targeted drugs and traditional Chinese medicine have shown good efficacy and tolerance in the treatment of cancer cachexia,such as ghrelin analogues,which promote growth and anabolic metabolism,and monoclonal antibodies which inhibit catabolic metabolism.The treatment of cachexy requires comprehensive intervention of clinical multidisciplinary collaboration,which can be controlled and even reversed.We made a comprehensive review on the progression of current drug therapy for cancer cachexia.